For UK Healthcare Professionals Only


Adverse events should be reported. Reporting forms and information can be found at: yellowcard.mhra.gov.uk
Adverse events should also be reported to Zydus Pharmaceuticals UK Ltd on 0800 9956034.

Zyduco-XL


Introducing Zyduco XL, A Cost-Effective, Bioequivalent Alternative to Mezavant® XL for Inflammatory Bowel Disease (IBD) treatment ¹–⁷


Please click here for Zyduco® XL prescribing information

Zyduco® XL (Mesalazine 1200mg) offers Integrated Care Boards (ICBs) a significant opportunity to reduce drug expenditure without compromising effectiveness or efficacy for you or your patients.1-7


  • Proven Bioequivalence: Fully licensed and clinically proven to be bioequivalent to the market-leading product, Mezavant® XL, ensuring the same therapeutic benefits and patient outcomes. 6


  •  Immediate Cost Savings: Offers 27% cost reduction on the standard 60-tablet pack compared to Mezavant® XL, with savings increasing to 29% on the larger 120-tablet pack. This not only helps optimise your healthcare budget but also contributes to reducing your carbon footprint by minimizing the need for frequent dispensing.2,3


  •  Substantial System-Wide Savings: For an average Integrated Care Board (ICB), a complete 100% conversion to this product could result in annual savings of approximately £70,000, representing significant financial benefits across the healthcare system.4,5


  •  Globally Established: This product has been available since 2016 in the United States, where it has successfully captured a 36% market share and now supports over 425,000 prescriptions each year, demonstrating its widespread acceptance.8


  •  Dedicated Transition Support: Zydus UK provides comprehensive support to facilitate a smooth and well-managed transition, including assistance with stock management and a range of communication tools and resources designed to support healthcare providers.


Zyduco® XL Cost Saving Calculator 9-10

Resources for HCPs

References

  1. Zyduco® XL 1200mg. Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/100638/smpc
    accessed August 2025
  2. https://dmd-browser.nhsbsa.nhs.uk/ Accessed March 2025
  3. https://www.drugtariff.nhsbsa.nhs.uk/ Accessed March 2025
  4. Data on File. Zydus Pharmaceuticals UK Ltd. [Cost calculator]
  5. Data on File. Zydus Pharmaceuticals UK Ltd. [Rx data UK]
  6. Data on File. Zydus Pharmaceuticals UK Ltd. [Bioequivalence data]
  7. Mezavant® XL 1200 mg. Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/6154/smpc
    Accessed August 2025
  8. Data on File. Zydus Pharmaceuticals UK Ltd. [Rx data US]
  9. NHS DM+D browser. services.nhsbsa.nhs.uk/dmd-browser/search
  10. NHS Business Services Agency. Drug Tariff Category C price. NHS Electronic Drug Tariff. www.drugtariff.nhsbsa.nhs.uk
    Savings are based on November 2025 Drug Tariff


Disclaimers:


This calculator calculates the potential cost difference for a ICB/Sub-ICBs/PCN - if Zydus Zyduco branded Mesalzine 1200mg MR Tabs are prescribed instead of Mezavant XL.

This calculator uses the pack usage information provided, and then uses current DM & D NHS list prices and Drug Tariff reimbursement prices to calculate the cost difference in prescribing.

Please note this is only an estimation based on current pricing as it is impossible to predict the future pricing of both generic and branded competitors. The source data for this model will be updated when necessary.

This data contains public sector information licensed under the Open Government Licence v3.0.

ZUK/WEB/HPA/25/11/01